Advaxis gets patent in Japan for cancer immunotherapy

|About: Advaxis Inc. (ADXS)|By:, SA News Editor

Advaxis (ADXS) has received a patent in Japan that covers the use of the company's ADXS-HPV immunotherapy product for the treatment of late-stage cervical cancer.

The IP is set to last until 2028.

Advaxis has over 40 patents worldwide and over 40 pending.

Shares are +6.6%. (PR)